Evaluation of novel orthotopic nude mouse models for human small-cell lung cancer

Journal of Thoracic Oncology

Volumn 8, Issue 2, 2013, Pages 140-146

  Isobe, Takeshi ^a,d   Onn, Amir ^b   Morgensztern, Daniel ^a   Jacoby, Jörg J ^a   Wu, Wenjuan ^a   Shintani, Tomoaki ^a   Itasaka, Satoshi ^a   Shibuya, Keiko ^a   Koo, Peter J ^a   O'Reilly, Michael S ^c   Herbst, Roy S ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c UNIVERSITY OF TEXAS   (United States)

^d SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Orthotopic model; Small cell lung cancer

Indexed keywords

CISPLATIN; ETOPOSIDE; IRINOTECAN; PACLITAXEL;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG SMALL CELL CANCER; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR CELL; TUMOR GROWTH; TUMOR VOLUME;

EID: 84873808119     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3182725ff9     Document Type: Article

References (21)

1. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006;24:4539-4544.
2. Shepherd FA, Crowley J, Van Houtte P, et al.; International Association for the Study of Lung Cancer International Staging Committee and Participating Institutions. The International Association for the Study of Lung Cancer lung cancer staging project: proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh) edition of the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 2007;2:1067-1077.
3. Kalemkerian GP, Akerley W, Bogner P, et al.; National Comprehensive Cancer Network. Small cell lung cancer. J Natl Compr Canc Netw 2011;9:1086-1113.
4. Noda K, Nishiwaki Y, Kawahara M, et al.; Japan Clinical Oncology Group. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 2002;346: 85-91.
5. Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 2006;24:2038-2043.
6. Lara PN Jr, Natale R, Crowley J, et al. Phase III trial of irinotecan/cisplatin compared with etoposide/cisplatin in extensive-stage small-cell lung cancer: clinical and pharmacogenomic results from SWOG S0124. J Clin Oncol 2009;27:2530-2535.
7. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999;17:658-667.
8. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-1229.
9. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer 1998;77:347-351.
10. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol 1985;3:1471-1477.
11. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 1999;17:1794-1801.
12. Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer 2012;13:115-122.
13. Onn A, Isobe T, Itasaka S, et al. Development of an orthotopic model to study the biology and therapy of primary human lung cancer in nude mice. Clin Cancer Res 2003;9:5532-5539.
14. Onn A, Isobe T, Wu W, et al. Epidermal growth factor receptor tyrosine kinase inhibitor does not improve paclitaxel effect in an orthotopic mouse model of lung cancer. Clin Cancer Res 2004;10:8613-8619.
15. Wu W, Onn A, Isobe T, et al. Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. Mol Cancer Ther 2007;6:471-483.
16. Kuo TH, Kubota T, Watanabe M, et al. Orthotopic reconstitution of human small-cell lung carcinoma after intravenous transplantation in SCID mice. Anticancer Res 1992;12:1407-1410.
17. Zakowski MF. Pathology of small cell carcinoma of the lung. Semin Oncol 2003;30:3-8.
18. Liu J, Johnston MR. Animal models for studying lung cancer and evaluating novel intervention strategies. Surg Oncol 2002;11:217-227.
19. Langley RR, Fidler IJ. Tumor cell-organ microenvironment interactions in the pathogenesis of cancer metastasis. Endocr Rev 2007;28: 297-321.
20. Hoffman R. Green fluorescent protein imaging of tumour growth, metastasis, and angiogenesis in mouse models. Lancet Oncol 2002;3: 546-556.
21. Poupon MF, Arvelo F, Goguel AF, et al. Response of small-cell lung cancer xenografts to chemotherapy: multidrug resistance and direct clinical correlates. J Natl Cancer Inst 1993;85:2023-2029.